Indictment Alleges $268 Million in False Claims Submitted to Medicare, TRICARE and Other Programs

Federal prosecutors allege Michael McMillan and his Protectus companies used reimbursement-linked discounts, disputed acquisition-price disclosures, billing assistance, and provider profit guarantees to cause Medicare, TRICARE, and CHAMPVA to pay approximately $268 million for skin-substitute wound-care claims.

WASHINGTON, DC — A federal indictment accuses Las Vegas businessman Michael McMillan of directing a nationwide wound-care reimbursement operation that allegedly caused Medicare, TRICARE, and CHAMPVA to pay approximately $268 million through false and fraudulent skin-substitute claims.

The government contends that McMillan and companies operating under the Protectus name linked product distribution, provider recruitment, claims assistance, reimbursement tracking, percentage-based invoices, and sales commissions in a commercial system built around payments from taxpayer-supported healthcare programs.

Although the proposed headline describes $268 million in claims submitted, the indictment states more precisely that government programs allegedly paid approximately $268 million, making the figure an asserted reimbursement total rather than merely the face value of unsuccessful billing attempts.

Prosecutors say approximately $174 million ultimately reached McMillan and Protectus, participating medical providers allegedly retained approximately $94 million, and sales representatives reportedly received another approximately $27 million from the portion collected by the Protectus businesses.

McMillan has not been convicted; every accusation remains subject to proof beyond a reasonable doubt, and the indictment represents the government’s untested account rather than evidence establishing that any defendant, provider, employee, or company committed a crime.

What the $268 Million Allegation Represents

According to the Northern District of Texas announcement describing the McMillan prosecution, the charged matter involves approximately $268 million in false and fraudulent claims for wound-care products billed to Medicare and other government healthcare benefit programs.

The underlying indictment identifies Medicare, TRICARE, and the Civilian Health and Medical Program of the Department of Veterans Affairs, commonly called CHAMPVA, as the public benefit programs that allegedly paid claims generated through the disputed arrangements.

Those programs serve different beneficiary populations, yet prosecutors allege that the same commercial framework linked them through skin-substitute applications, reimbursement-dependent provider invoices, alleged pricing misrepresentations, and financial rewards for medical practices and recruiting representatives.

The $268 million amount does not necessarily equal a final criminal loss, restitution judgment, or forfeiture order, because those calculations can change through evidentiary rulings, legitimate-value arguments, coverage analysis, tracing disputes, factual stipulations, and judicial findings.

It nevertheless provides the prosecution’s central measure of scale, showing why federal investigators treated the Protectus network as a major national healthcare fraud matter rather than an isolated billing disagreement involving a single clinic or individual claim.

Three Federal Programs Allegedly Funded the Claims

Medicare occupies the most detailed position within the charging document because prosecutors describe specific claim-form requirements, provider communications, reimbursement reports, and acquisition-price representations that allegedly determined how much the program paid for each skin-substitute application.

TRICARE extends the alleged harm to the military healthcare system serving eligible active-duty personnel, retirees, and families, while CHAMPVA generally supports qualifying spouses, surviving spouses, and children connected with veterans who meet defined eligibility requirements.

By naming all three programs, prosecutors portray a reimbursement strategy that allegedly spanned public insurance systems rather than depending on one administrator, one region, one medical specialty, or one narrowly confined group of beneficiaries.

The multi-program allegations also explain why investigators included the Federal Bureau of Investigation, federal health inspectors, defense investigators, and veterans-affairs investigators, each contributing distinct authority, claims expertise, financial records, beneficiary-program knowledge, and specialized oversight.

Why Skin Substitutes Can Generate Large Reimbursements

Skin substitutes include specialized biological or synthetic wound-care materials that may support healing when appropriately selected for chronic, difficult, or nonresponsive wounds, particularly after conventional therapies fail and documented clinical criteria support advanced treatment.

Government reimbursement can depend substantially upon the product used and the number of square centimeters applied, meaning product selection, wound measurement, discarded material, treatment frequency, acquisition price, and supporting documentation can materially affect payment.

That structure can produce very large claim values for expensive products applied across significant surface areas, creating legitimate opportunities for advanced care while also increasing enforcement concerns when commercial compensation becomes tied directly to reimbursement volume or value.

The McMillan indictment focuses on the financial eligibility and accuracy of the claims, alleging that hidden remuneration and disputed price disclosures caused government programs to reimburse transactions they would not have paid had the arrangements been reported accurately.

The prosecution therefore does not need to argue that skin substitutes are inherently improper, because its theory instead examines how products were marketed, financed, billed, priced, disclosed, and connected with payments allegedly offered to induce federally reimbursed business.

Protectus Allegedly Coordinated the Reimbursement Chain

The indictment defines Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC collectively as Protectus and alleges that McMillan owned and controlled all six Nevada companies.

Through that group, prosecutors say skin-substitute products reached physicians, podiatrists, nurse practitioners, and other providers without customary upfront payment, allowing practices to use products first and await government reimbursement before receiving corresponding invoices.

Protectus personnel allegedly assisted providers with claims, monitored whether government programs approved reimbursement, calculated invoices from the amounts collected, communicated about resubmissions, and compensated sales representatives after participating practices paid the companies in full.

This asserted continuity makes Protectus central to the government’s false-claims narrative, because one interconnected organization allegedly possessed visibility into product delivery, claim preparation, payment status, provider retention, representative commissions, and corporate receipts throughout the transaction cycle.

Defense counsel may dispute whether those activities reflected ordinary distribution, credit, billing support, and collection services within a complex marketplace, while prosecutors will likely argue their combined economic purpose reveals deliberate participation in fraudulent reimbursement.

No Upfront Payment Allegedly Reduced Provider Risk

Participating practices allegedly received skin substitutes without paying their acquisition cost before treatment, a feature that removed immediate inventory expense and allowed providers to submit claims before knowing whether Medicare, TRICARE, or CHAMPVA would approve reimbursement.

When a government program denied a claim, prosecutors say Protectus generally did not invoice the provider, meaning the practice allegedly avoided responsibility for product cost while the intermediary absorbed or otherwise managed the unsuccessful reimbursement outcome.

When a claim succeeded, however, Protectus allegedly issued an invoice calculated as approximately sixty to seventy percent of the government payment, leaving the provider with approximately thirty to forty percent and frequently thousands of dollars from one application.

The indictment characterizes the retained share as illegal remuneration disguised as a rebate or discount, alleging that the promised profit encouraged providers to order and use Protectus products for beneficiaries covered by public healthcare programs.

Commercial discounts are not automatically criminal, and qualifying arrangements may receive statutory or regulatory protection, but prosecutors contend the Protectus model depended upon successful reimbursement and guaranteed margins rather than an independently established, accurately reported acquisition price.

Jurors may ultimately need to decide whether the percentage structure represented lawful commercial risk allocation or an intentionally concealed kickback, requiring close examination of contracts, invoices, presentations, communications, payment practices, and participant understanding.

How an Alleged Kickback Can Affect Claim Eligibility

Federal healthcare claims can become false or ineligible when services or products are procured through prohibited remuneration, even if a patient received something clinically useful, because compliance with payment conditions can matter in government reimbursement decisions.

Prosecutors will likely argue that promised provider profits corrupted purchasing judgment and rendered the resulting claims unpayable, while the defense can question whether the remuneration was unlawful, whether each claim depended on it, and whether providers chose medically appropriate treatment independently.

That dispute separates the existence of a wound-care procedure from the legal validity of its reimbursement, since a product may have been physically applied while the associated claim remains challenged because of inducements, pricing information, or program-specific billing rules.

The indictment’s fraud theory therefore rests on more than the size of payments, linking financial promises to alleged misrepresentations that supposedly prevented program administrators from seeing the effective prices and reimbursement-dependent economics behind each provider arrangement.

If jurors reject the government’s characterization of the discounts or find disputed disclosures immaterial, the prosecution’s broad claims theory could weaken, demonstrating why evidence about knowledge, purpose, reporting duties, and payment causation will be essential.

Acquisition-Price Reporting Sits at the Center of the Case

The indictment alleges that providers submitting certain Medicare claims were required to disclose their actual acquisition price, including relevant discounts, rebates, refunds, and other price adjustments, within Box 19 of the professional claim form.

Prosecutors contend that McMillan and Protectus submitted claims, assisted with submissions, or instructed providers to report inflated acquisition prices that did not account for the reimbursement-linked reductions allegedly embedded within the Protectus invoicing system.

Under that theory, the government paid claims using incomplete or inaccurate information because the reported price allegedly exceeded what practices ultimately owed after Protectus calculated invoices from successful reimbursements and allowed providers to retain agreed percentages.

The alleged misstatement matters because Medicare administrators assessing coverage and payment must understand the real economic transaction, not simply an invoice figure that prosecutors claim concealed rebates, guaranteed profits, or adjustments determined after reimbursement arrived.

During a March 2024 meeting described in the indictment, McMillan allegedly said that he reviewed every Medicare claim to ensure Protectus products were billed at prices above what participating providers actually paid for those materials.

Defense attorneys can challenge the recollection, context, completeness, interpretation, and legal significance of that alleged statement, while also examining whether providers controlled final submissions, billing instructions were ambiguous, or employees departed from formal company policies.

Invoices Allegedly Documented Percentage Splits

One October 2022 accounting example described by prosecutors recorded a provider collection of $53,625.60, a provider-retained amount of $16,087.68, and a Protectus Technologies invoice of $37,537.92, reflecting an exact thirty-to-seventy allocation.

The government may present that record as evidence that the provider’s obligation arose from reimbursement rather than a predetermined wholesale price, while the defense may argue one invoice cannot define every agreement, transaction, or participant’s understanding.

In another episode from July 2023, a Texas practice employee allegedly disputed an invoice exceeding $82,000 because its calculation reflected thirty-five-percent provider profit even though a newer agreement reportedly promised the practice a forty-percent share.

McMillan allegedly directed a Protectus employee to correct that invoice, an exchange prosecutors may use to show personal oversight of the reimbursement formula, subject to defense arguments concerning commercial context, contractual interpretation, and lawful discount practices.

Taken together, the examples give jurors concrete arithmetic to compare against broader testimony, but prosecutors must still connect individual documents with fraudulent intent and cannot establish an entire nationwide conspiracy through isolated accounting entries alone.

Billing Assistance Allegedly Helped Denied Claims Return

Protectus personnel allegedly did more than deliver products and send invoices, because the indictment describes employees assisting medical practices with billing questions, missing information, reimbursement tracking, claim corrections, and resubmission after government payment denials.

During a May 2024 exchange, a provider reportedly advised Protectus that Medicare had paid $9,024 for one product claim while denying another, after which an employee allegedly identified missing Box 19 information and recommended resubmission.

Protectus then allegedly issued a $5,865.60 invoice for the paid claim, equaling sixty-five percent of the reported reimbursement and leaving the practice with thirty-five percent, directly linking billing guidance to the challenged percentage-based payment structure.

Prosecutors may argue this sequence demonstrates operational knowledge and active claim participation, while the defense may emphasize that lawful vendors routinely help customers resolve coding, documentation, coverage, and administrative errors without assuming responsibility for clinical representations.

The legal significance will depend upon what information Protectus supplied, whether anyone knowingly misstated material facts, who certified each claim, and whether billing assistance advanced fraud rather than helping providers seek payment for legitimately covered treatment.

Recruiting Medical Providers Expanded the Alleged Scheme

Sales representatives allegedly introduced physicians, podiatrists, nurse practitioners, and other providers to the Protectus arrangement, presenting not only the available products but also the percentage of government reimbursement that a participating practice could expect to retain.

At the March 2024 meeting cited by prosecutors, McMillan allegedly described an average provider rebate of thirty-five percent and explained that a practice collecting $180,000 monthly from Medicare could retain approximately $63,000 under the proposed arrangement.

That earnings illustration may support the allegation that financial gain induced product orders, although defense lawyers may characterize it as transparent commercial pricing information rather than a concealed payment intended to override independent clinical judgment.

The indictment identifies five anonymized providers practicing in Arlington, Dallas, and McKinney, Texas, along with Santa Monica, California, and Payson, Utah, illustrating the multistate scope prosecutors attribute to the Protectus recruitment system.

Responsible reporting should not speculate about unnamed providers or presume wrongdoing by every clinician, patient, employee, or representative connected with Protectus, because individual knowledge, conduct, defenses, and charging decisions may differ substantially from person to person.

Sales Commissions Allegedly Followed Successful Collections

Representatives who recruited providers allegedly received commissions calculated from amounts Protectus collected after government reimbursement, extending the payment-dependent financial structure beyond medical practices and into the sales network responsible for expanding product utilization.

Prosecutors estimate that Protectus paid approximately $27 million to representatives associated with participating providers, while commission reports allegedly tracked insurer payment status before corresponding compensation became available for distribution through the company accounting process.

An email exchange from November 2022 reportedly concerned a commission statement totaling $44,035.92 and an omission exceeding $6,400, with a Protectus employee explaining that commissions depended upon insurance payments reported by the provider’s office.

The defense may argue percentage-based sales compensation is common and lawful, while prosecutors may contend its link to allegedly illegal provider remuneration and disputed claims shows coordinated incentives operating throughout the same reimbursement chain.

The Alleged Money Flow Explains the Government’s Theory

The indictment’s financial narrative begins when a provider applies a Protectus skin substitute and submits a government claim, continues when reimbursement arrives, and divides that payment among the practice, Protectus entities, and representatives according to alleged formulas.

Of the approximately $268 million allegedly paid, providers reportedly retained roughly $94 million, and Protectus received approximately $174 million, meaning the two figures broadly account for the government reimbursement before representative commissions paid from company receipts.

The roughly $27 million in representative compensation should therefore not be added independently to produce a larger claim total, because prosecutors describe those commissions as downstream payments from money already included within Protectus collections.

An NBC 5 Dallas-Fort Worth investigation reviewing the unsealed cases reported the alleged provider and representative payments and described accusations involving luxury homes, vehicles, and a private aircraft purchased with disputed proceeds.

Investigators can test the asserted flow using government reimbursement data, provider bank records, Protectus accounts, accounting ledgers, invoices, commission statements, emails, claim forms, and asset transactions, creating multiple documentary points to corroborate or challenge the allegations.

False Claims Do Not Automatically Mean Treatment Never Occurred

The phrase false claims can describe several legally distinct problems, including nonexistent services, medically unnecessary treatment, falsified diagnoses, misrepresented pricing, undisclosed kickbacks, incorrect quantities, ineligible providers, or products procured through prohibited financial inducements.

In McMillan’s case, the indictment emphasizes the alleged remuneration system and acquisition-price representations, so the public should not assume every skin substitute was never applied, every wound lacked clinical need, or every associated patient received worthless care.

Prosecutors can nevertheless argue that a physically delivered product generated a false claim when hidden kickbacks or knowingly inaccurate price information made reimbursement unavailable, while defense lawyers can contest materiality, intent, eligibility, and claim-specific causation.

This distinction protects accuracy in public reporting because the $268 million allegation addresses the government’s theory of fraudulent payment, not a final judicial determination that every dollar reflected fabricated treatment or caused identical patient harm.

Clinical records may still matter as the parties examine product selection, wound measurements, application frequency, documentation, and medical necessity, but the indictment’s central narrative concerns allegedly corrupted financial and billing relationships affecting reimbursement.

Nine Criminal Counts Present Different Questions

Count One charges McMillan with conspiracy to commit healthcare fraud, alleging an agreement to obtain government healthcare money through materially false and fraudulent pretenses connected with the skin-substitute claims and Protectus provider arrangements.

Count Two charges a conspiracy to defraud the United States and to offer or pay illegal healthcare kickbacks and bribes, focusing upon alleged interference with lawful program administration and remuneration intended to generate federally reimbursed orders.

Counts Three through Nine address seven monetary transactions exceeding $10,000 in property allegedly derived from the charged conspiracies, identifying four real-estate interests, two luxury vehicles, and a Cessna Citation VII private aircraft.

Those transaction counts require proof concerning criminally derived property and McMillan’s knowledge, but they do not necessarily require prosecutors to show every purchase was structured specifically to conceal ownership, source, or control of the money.

Different evidence and defenses may therefore apply across the nine counts, allowing jurors to evaluate the underlying reimbursement arrangements separately from each later property transaction and potentially reach different conclusions concerning individual allegations.

Data Analytics and Ordinary Records Could Drive the Evidence

Federal healthcare investigations increasingly begin with payment analytics identifying unusual growth, product concentration, provider outliers, repeated billing patterns, or geographically dispersed claims that share common suppliers, representatives, pricing, or financial characteristics across numerous jurisdictions.

Once investigators identify a pattern, subpoenas and search procedures can gather claims, medical records, contracts, invoices, reimbursement notices, emails, commission reports, bank statements, corporate ownership materials, and electronic communications spanning multiple years of operations.

The alleged McMillan scheme ran from about May 2019 through February 2026, giving prosecutors and defense experts an extensive record to test whether invoices, payments, and communications followed consistent or changing commercial practices.

Jurors may hear competing interpretations of the same documents, with government witnesses describing concealed reimbursement sharing while defense experts characterize delayed invoicing, contingent credit, commercial discounts, billing assistance, and commissions as legitimate features of product distribution.

The Case Emerged from a National Enforcement Campaign

McMillan’s indictment formed part of the 2026 National Health Care Fraud Takedown, which federal officials said charged 455 defendants, including ninety doctors and other licensed professionals, across alleged schemes involving more than $6.5 billion in false claims.

The coordinated initiative covered fifty-six federal districts and forty-five states and territories; every state Medicaid Fraud Control Unit participated, and authorities announced more than $182 million in nationwide seizures of cash, vehicles, jewelry, and other property.

Within the Northern District of Texas, thirteen defendants faced seven separate prosecutions involving more than $365 million in alleged fraudulent billing, making McMillan’s wound-care case the district’s largest announced matter by claimed reimbursement scale.

That national context explains the case’s visibility but cannot prove McMillan’s guilt, because allegations involving other defendants, healthcare sectors, billing companies, or wound-care businesses must not substitute for admissible evidence tied to his nine counts.

Patients and Taxpayers Carry the Broader Risk

Chronic wounds can expose older adults, people with diabetes, veterans, military families, and medically fragile patients to infection, hospitalization, amputation, severe pain, and reduced mobility, making reliable access to appropriate treatment profoundly important.

Financial incentives tied to product value or reimbursement may threaten independent decision-making when they influence which material is selected, how much is applied, how frequently treatment occurs, or whether documentation accurately supports program requirements.

At the same time, enforcement narratives should not stigmatize legitimate wound-care clinicians or discourage medically necessary treatment, because skin substitutes can provide meaningful benefits when patient selection, product use, documentation, billing, and financial relationships satisfy governing standards.

The public interest therefore requires both vigorous investigation of intentional fraud and careful preservation of the presumption of innocence, ensuring taxpayer protection does not become a license for unsupported conclusions about uncharged providers or vulnerable patients.

Compliance Lessons Extend Across Wound Care

Manufacturers, distributors, medical practices, billing companies, and marketers should examine whether product invoices remain payable after denied claims, whether discounts are established independently, and whether every adjustment appears accurately within required program disclosures.

Compliance teams should test whether providers receive guaranteed reimbursement percentages, whether representatives are compensated from successful collections, whether sales personnel influence claim information, and whether clinical decisions remain insulated from vendor-directed financial pressure.

Organizations should preserve contracts, presentations, text messages, emails, invoices, claim forms, reimbursement reports, commission spreadsheets, and accounting records because routine business materials can later establish knowledge, control, intent, consistency, or contradictory explanations during an investigation.

Independent reviewers should also sample claims across providers and time periods, compare represented acquisition prices with final economic cost, document corrective actions, and investigate unusual profitability before questionable practices become entrenched across an expanding network.

No compliance checklist can decide criminal liability by itself, yet timely internal review can identify reimbursement-dependent arrangements that require legal analysis, repayment consideration, policy revision, employee discipline, or disclosure to appropriate authorities after further review.

Reputational Consequences Begin Before Trial

An indictment linking taxpayer healthcare payments to alleged kickbacks and luxury assets can immediately dominate search results, damaging commercial relationships, employee confidence, patient trust, and professional standing years before litigation produces a final resolution.

Organizations facing that imbalance may need disciplined crisis public-relations management that separates accusations from established facts, protects patient confidentiality, coordinates approved statements, corrects demonstrable inaccuracies, and avoids commentary that could undermine ongoing legal proceedings.

Longer-term reputation-rebuilding strategies can publish accurate procedural updates, explain verified compliance reforms, address legitimate stakeholder concerns, and preserve searchable context without hiding material developments or presenting unresolved allegations as adjudicated facts in court.

McMillan, Protectus, providers, representatives, employees, patients, and third parties occupy different legal and reputational positions, making individualized communications essential whenever a broad response could imply collective guilt, reveal protected information, or contradict defense strategy.

What Happens Next in Federal Court

Pretrial proceedings may examine search procedures, claim data, Box 19 requirements, product pricing, corporate records, bank transactions, witness credibility, expert methods, provider agreements, commission structures, and the admissibility of statements attributed to McMillan or Protectus personnel.

Prosecutors must prove that McMillan knowingly joined the charged conspiracies and possessed the required awareness for each monetary transaction, while defense counsel can challenge intent, materiality, attribution, program rules, tracing, and witness reliability.

Any eventual loss, restitution, forfeiture, or sentencing determination would depend upon sustained counts, proven facts, legitimate value, recovered assets, guideline findings, criminal history, role assessments, obstruction issues, victim evidence, and individualized judicial discretion.

Assets valued at approximately $35 million were reportedly seized during the investigation, but seizure does not establish guilt or permanent forfeiture, and ownership, tracing, valuation, proportionality, liens, and third-party interests may remain disputed.

The government’s $268 million theory will ultimately depend upon admissible evidence showing which claims were submitted, why program administrators paid them, what information was inaccurate, how remuneration influenced business, and what McMillan allegedly knew.

Until a jury returns verdicts or another lawful resolution ends the prosecution, Michael McMillan remains presumed innocent, the approximately $268 million figure remains an allegation, and every disputed claim, rebate, invoice, commission, and transaction remains open to adversarial testing.